Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
10.51
+0.44 (4.37%)
At close: Aug 4, 2026, 4:00 PM EDT
10.45
-0.06 (-0.57%)
Pre-market: Aug 5, 2026, 4:39 AM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
770.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Rigel Pharmaceuticals | 299.77M |
| Phathom Pharmaceuticals | 239.66M |
| Aclaris Therapeutics | 8.37M |
| Oculis Holding AG | 1.40M |
CADL News
- 1 day ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - GlobeNewsWire
- 6 days ago - Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston - GlobeNewsWire
- 23 days ago - Candel Therapeutics initiated with a Buy at Stifel - TheFly
- 27 days ago - Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire